August 2012
-
Glenmark Pharmaceuticals and SaNOtize have announced the approval of FabiSpray nitric oxide nasal spray (NONS) for the treatment of COVID-19 by the Drugs Controller General of India (DCGI) and the launch of the nasal spray… Read more . . .
-
The FDA has now fully approved Lupin’s ANDA for its generic version of Sunovion’s Brovana arformoterol tartrate inhalation solution for the treatment of COPD. Brovana was approved by the FDA in 2006. The agency tentatively… Read more . . .
-
Celltrion Group announced that it has submitted an IND application for a Phase 3 trial of an inhaled COVID-19 antibody cocktail for the treatment of mild-to-moderate COVID-19. In July 2021, Celltrion announced that it had… Read more . . .
-
Aptar Pharma announced that it has launched a metered dose inhaler add-on sensor called HeroTracker Sense. According to Aptar, the device has been CE marked and is “pending FDA approval.” HeroTracker inhaler sensors were originally developed… Read more . . .
-
Third Pole Therapeutics announced that it has raised an additional $25 million in a financing round led by existing investors for continued development of its tankless inhaled nitric oxide (iNO) systems. The company also said… Read more . . .
-
Biocorp and RxPack have announced a new distribution agreement giving RxPack the exclusive rights to commercialize Biocorp’s Inspair inhaler sensor in Eastern Europe, Southeast Asia, South America, and the Middle East. Lindal had obtained the… Read more . . .
-
Ethris GmbH said that it has closed a $26.3 million Series B financing round led by Laureus Capital, with proceeds earmarked for continued development of the company’s ETH47 and ETH42 inhaled mRNA based therapies, which… Read more . . .
-
Aridis Pharmaceuticals announced that it has received an award of $1.9 million from the Bill & Melinda Gates Foundation to fund preclinical development of inhaled monoclonal antibodies against influenza and SARS-CoV-2. Aridis is developing both… Read more . . .
-
Intranasal vaccine developer Leyden Laboratories has closed a $140M Series B financing led by Casdin Capital and GV, the company said. Proceeds will go toward development of the company’s pipeline, which includes its PanFlu intranasal… Read more . . .
-
Opiant gets additional $2.2 million in BARDA funding for development of OPNT003 intranasal nalmefene
According to Opiant Pharmaceuticals, the company’s contract with the Biomedical Advanced Research and Development Authority (BARDA) has been amended to provide an additional $2.2 million to support activities related to a 505(b)(2) NDA submission for OPNT003 nalmefene… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.